Cerner Enviza Aims To Accelerate Therapies And Improve Patient Outcomes

Rhea-AI Summary

Cerner Corporation (NASDAQ: CERN) has launched Cerner Enviza, a new operating unit focused on data-driven healthcare solutions. This initiative aims to reduce the average 17-year timeline and $2.5 billion cost for new therapies to reach patients, while promoting equitable participation in clinical trials. By combining resources from Cerner and Kantar Health, the unit seeks to leverage extensive health data to enhance research and therapy development. The goal is to improve patient outcomes through faster, more efficient delivery of healthcare solutions.

Positive

• Launch of Cerner Enviza aims to reduce therapy development costs and timelines.
• Combines expertise of Cerner and Kantar Health for enhanced data-driven solutions.
• Focus on increasing participation in clinical trials for more equitable results.

Negative

• None.

Combining decades of healthcare, life sciences and collaborative research to transform the way care is delivered

KANSAS CITY, Mo., Oct. 26, 2021 (GLOBE NEWSWIRE) -- Cerner Corporation (NASDAQ: CERN), a global healthcare technology company, announces the launch of a new operating unit, Cerner Enviza^SM, that offers data-driven solutions and research services to help bring clarity to multi-dimensional data through real-world evidence and insights. The combined expertise of the Cerner and Kantar Health teams is expected to help accelerate discovery, development and deployment of therapies and advance clinical research and the life sciences industry to improve everyday health.

Today, new therapies can take on average 17 years and $2.5 billion to finally reach patients. Cerner Enviza was established to unlock the power of data and a network of research-ready health systems to help get therapies to patients more quickly and at less expense. In addition, a key focus will be on broadening the availability and participation in trials to help achieve more equitable results. For example, according to one study only 3% of physicians and patients participate in trials​ and only a fraction of eligible patients receive the new treatments​.

“The true promise of the digital age is to use data to improve everyday health around the world,” said David Feinberg, M.D., president and CEO, Cerner. “Healthcare is far too complex, inefficient and expensive. We have to break down industry silos and evolve from simply accumulating data to generating meaningful insights that can accelerate therapy development. With Cerner Enviza, we can arm researchers with diverse tools and datasets to help them address these challenges and help change the way we develop and deliver care for our patients."

For more than 20 years, Cerner has offered research and real-world data solutions to help caregivers and investigators launch or advance their efforts. Kantar Health worldwide has spent years helping life sciences researchers leverage data – both quantitative and qualitative – to better understand patient and treatment journeys. Cerner Enviza is dedicated to not only connecting – but bridging – industry and technology boundaries.

“With Cerner Enviza, we bring together the expertise, assets and capabilities of Kantar Health with Cerner’s technology and access to a large collection of deidentified patient health data,” said Mike Kelly, Global Head of Cerner Enviza. “Our approach unites the life sciences and healthcare providers to support research and trial opportunities across this ecosystem. The goal is to significantly reduce the timeframe and cost from idea to therapy delivery to help achieve better patient outcomes.”

Cerner Enviza aims to accelerate the discovery, development and delivery of extraordinary insights and therapies to improve everyday health for people globally. By combining decades of innovation, life sciences knowledge and collaborative research, Cerner Enviza provides data-driven solutions and expertise that helps bring remarkable clarity to healthcare’s most important decisions. For more information, visit www.cernerenviza.com.

About Cerner
Cerner’s health technologies connect people and information systems at thousands of contracted provider facilities worldwide dedicated to creating smarter and better care for individuals and communities. Recognized globally for innovation, Cerner assists clinicians in making care decisions and assists organizations in managing the health of their populations. The company also offers a connected clinical and financial ecosystem to help manage day-to-day revenue functions, as well as a wide range of services to support clinical, financial and operational needs, focused on people. For more information, visit Cerner.com, The Cerner Blog or connect on Facebook, Instagram, LinkedIn, Twitter or The Cerner Podcast. Nasdaq: CERN. Healthcare is too important to stay the same.

Media Contact: 
Cerner 
Stephanie Greenwood, stephanie.greenwood@cerner.com

All statements in this press release that do not directly and exclusively relate to historical facts constitute forward-looking statements. These forward-looking statements are based on the current beliefs, expectations and assumptions of Cerner's management and could differ materially from those expressed in such forward-looking statements. The words “believe”, “aim”, “will”, “can”, “goal” or the negative of these words, variations thereof or similar expressions are intended to identify such forward-looking statements. For example, our forward-looking statements include statements regarding the future benefits or synergies of the Kantar Health acquisition and the Cerner Enviza offering. Factors that could cause or contribute to such differences include, but are not limited to: the extent to which the COVID-19 pandemic and measures taken in response thereto could adversely affect our financial condition, future bookings and results of operations; significant competition and our ability to anticipate or respond quickly to market changes, changing technologies and evolving pricing and deployment methods and to bring this competitive offering to market in a timely fashion; risks inherent with business acquisitions, strategic investments, collaborations and the failure to achieve projected synergies, or divestitures; managing growth in the new markets in which we offer solutions, health care devices or services; long sales cycles for our solutions and services; risks associated with the loss or recruitment and retention of key personnel or the failure to successfully develop and execute succession planning to assure transitions of key associates and their knowledge, relationships and expertise; changing political, economic and regulatory influences, which could impact the purchasing practices and operations of our clients and increase costs to deliver compliant solutions and services; non-compliance with laws, regulations or certain industry initiatives or failure to deliver solutions or services that enable our clients to comply with laws or regulations applicable to their businesses; and, failure of the parties to achieve the intended synergies. Additional discussion of these and other risks, uncertainties and factors affecting Cerner's business is contained in Cerner's filings with the Securities and Exchange Commission. The reader should not place undue reliance on forward-looking statements, since the statements speak only as of the date that they are made. Except as required by law, Cerner undertakes no obligation to update or revise forward-looking statements to reflect changed assumptions, the occurrence of unanticipated events, or changes in our business, results of operations or financial condition over time.

FAQ

What is Cerner Enviza and how will it impact healthcare?

Cerner Enviza is a new unit launched by Cerner Corporation focused on offering data-driven healthcare solutions aimed at accelerating the development and delivery of therapies.

How long does it typically take for new therapies to reach patients?

On average, new therapies take about 17 years and cost approximately $2.5 billion to reach patients.

What are the goals of Cerner Enviza?

Cerner Enviza aims to unlock health data potential to reduce therapy development timelines and improve patient access to treatments.

What is the significance of the partnership between Cerner and Kantar Health?

The partnership combines Cerner's healthcare technology with Kantar Health's data expertise to enhance research and improve healthcare outcomes.

What challenges does Cerner face with the launch of Cerner Enviza?

Cerner may face challenges from significant competition, managing growth in new markets, and ensuring the successful integration of resources from Kantar Health.